Agmatine
Best-in-class: Agmatine
An arginine metabolite used pre-workout for nitric-oxide pumps and as a neuromodulator for mood and pain support.
Agmatine quick facts
| Suggested dose | 500–1,000 mg pre-workout. |
| How often | Per training session |
| Who it's for | Pumps/blood flow and mood/pain-modulation experimenters. |
The vasodilation rationale is muddier than it looks, since agmatine inhibits some NOS isoforms rather than uniformly increasing nitric oxide. Human performance data is thin. The more interesting evidence is in neuropathic pain, where small trials are positive. Worth understanding that you are buying a compound whose best evidence is for something other than what the label emphasizes.
How Agmatine actually works
Agmatine is decarboxylated arginine and acts on several systems rather than one — it modulates nitric oxide synthase isoforms differentially, binds imidazoline receptors, and antagonizes NMDA receptors. That last property is the basis of interest in neuropathic pain and mood, which is arguably better founded than the pump claim it is usually sold for.
Where to get Agmatine
Find Agmatine on iHerb →The evidence for Agmatine
Graded by what exists behind each claim.
✅ Clinically validated
- Popular for enhanced pumps/blood flow (nitric oxide) and studied for neuropathic pain and mood modulation.
- Human performance data is limited but mechanistically supported.
📊 Correlative data
- NO-mediated blood flow tracks with training pumps.
🧪 Theoretical / extrapolated benefits
- Nootropic and pain-modulating roles are emerging but not firmly established in humans.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Agmatine actually does
Agmatine is decarboxylated arginine: take L-arginine, remove the carboxyl group with arginine decarboxylase, and what remains is a short, doubly-charged guanidino-amine. It is destroyed by agmatinase, which cleaves it to putrescine and urea, and by diamine oxidase. Those two enzymes are the reason the dose on a pre-workout label and the dose in the only controlled trial are so far apart.
The receptor pharmacology is unusually well characterized for a supplement, and it is not the pharmacology on the label. The reviews that define this molecule describe it as a ligand at imidazoline I1 and I2 sites and at alpha-2 adrenergic receptors, a blocker of the NMDA receptor channel, and an inhibitor of nitric oxide synthase Reis 2000Halaris 2007. Read that list again with a pre-workout label in your other hand. Agmatine is sold as a nitric-oxide product for vasodilation and pumps. The published pharmacology says it inhibits the enzyme that makes nitric oxide.
And the second half of the same problem is transport. Agmatine and arginine are structurally close enough to share the cationic amino acid transporters that carry arginine into endothelial cells. Competition at that transporter would reduce the intracellular arginine available to endothelial nitric oxide synthase — which points the same way as the enzyme inhibition. So the mechanism for the claim this product is actually bought for runs backwards at two independent steps. That is labeled extrapolation on the transport half, and it is a straightforward reading of the reviews on the enzyme half Reis 2000.
What agmatine plausibly does do is neuromodulation, and the NMDA channel is the specific target. Blocking the NMDA receptor channel is the mechanism behind the pain and mood claims, because NMDA-dependent central sensitization is what turns an acute nerve injury into persistent neuropathic pain Reis 2000Halaris 2007. It is also why the human trials that exist are pain trials and not performance trials — the people who studied this molecule seriously went where the pharmacology pointed.
The imidazoline story is the one to watch and the least developed. I1 receptors are the target of clonidine's antihypertensive cousins, moxonidine and rilmenidine, which is the mechanistic reason agmatine lowers blood pressure Reis 2000. That is a real, drug-class-level action sitting inside a bodybuilding supplement, and it belongs in the safety section rather than the marketing.
Cell, rodent, human — and where it stops
In cells. Radioligand binding at imidazoline and alpha-2 sites, patch-clamp block of NMDA channels, and nitric oxide synthase assays — the pharmacology is real and it is thirty years old Reis 2000.
In rodents. Rats and mice, intraperitoneal or intracerebroventricular injection, across pain, mood, addiction and neuroprotection models Halaris 2007. Note the routes. Almost the entire preclinical case for agmatine was built by putting it directly into the abdominal cavity or into a cerebral ventricle, which bypasses both the gut and the diamine oxidase in the intestinal mucosa that exists to destroy amines like this one. An oral human dose is not a small version of that experiment; it is a different experiment.
In people, there is exactly one controlled trial. An open-label dose-escalating study across four cohorts at 1.335 to 3.560 grams a day for ten to twenty-one days, followed by a randomized, double-blind, placebo-controlled trial in 99 participants — 51 on agmatine sulfate, 48 on placebo — for fourteen days, in lumbar-disc-associated radiculopathy. The agmatine group improved by 26.7% and 70.8% on the two endpoints against 6.0% and 20.0% on placebo (P ≤ 0.05) Keynan 2010. Everything else in the human literature is smaller and uncontrolled: an open-label consecutive case series in painful small fiber neuropathy Rosenberg 2020, and a single-patient report of five years of high daily dosing Gilad 2014.
The specific obstacle is that the one trial is at four to seven times the dose on the bottle, for a completely different indication. The trial ran at 1.335–3.560 g/day for sciatic pain Keynan 2010. This site's card says 500–1,000 mg pre-workout for pumps. There is no overlap in dose, no overlap in indication, and no controlled human performance trial of agmatine at all. A reader taking 750 mg before the gym is not taking a smaller dose of a proven intervention; they are outside the evidence in two dimensions at once.
The second obstacle is that one research group wrote almost all of it. The dose-escalation trial, the neuropathy case series and the five-year safety report share an author Keynan 2010Rosenberg 2020Gilad 2014. That is not misconduct and it is not a reason to discard the work. It is a reason to say plainly that no independent group has replicated the only positive controlled result in this literature.
Agmatine — which form, and does it matter
Agmatine sulfate is the only form with any human data, and the salt is not cosmetic. Free-base agmatine is a hygroscopic, unstable oil; the sulfate is a stable crystalline solid, and it is what the trials used Keynan 2010. A label that says only ‘agmatine’ has not told you which it contains, and the sulfate salt is roughly two-thirds agmatine by weight — so 1,000 mg of agmatine sulfate is not 1,000 mg of agmatine. Nobody in this market states which basis they are quoting.
The dose gap deserves stating as arithmetic. The controlled trial's range was 1.335 to 3.560 grams a day Keynan 2010. At the card's 500–1,000 mg, a reader is at roughly a fifth to a half of the bottom of the tested range, and at the top of the trial range they would be taking three and a half grams — which is where the gastrointestinal complaints start.
Pre-workout timing is a convention, not a finding. No human pharmacokinetic study of oral agmatine sulfate defines a time to peak plasma concentration, so ‘30 minutes before training’ is borrowed from caffeine. The pain trial dosed daily for two weeks rather than acutely Keynan 2010, and the mechanisms with actual evidence behind them — NMDA channel block, imidazoline signaling Reis 2000 — are not acute-performance mechanisms. If you are taking this for pain or mood, daily dosing is what was studied; if for pumps, nothing was studied.
Empty stomach, and for a specific reason. Diamine oxidase in the intestinal mucosa degrades dietary amines, and a large protein meal loads it. Taking agmatine away from food should reduce first-pass destruction. Labeled extrapolation: nobody has measured plasma agmatine fed versus fasted in a human.
What would have to be true, and how you would know it was not
1. Blood pressure down 3–6 mmHg systolic within two weeks of daily dosing at a gram or more. Imidazoline I1 agonism is the mechanism of a licensed antihypertensive class Reis 2000Halaris 2007, and this site's card already notes the effect. Home cuff, seated, seven consecutive mornings averaged, before and after. This is the most likely thing to happen and nobody buys the product for it.
2. Neuropathic pain down 25–70% on validated scoring at 14 days, at 1.3–3.5 g/day. Those are the trial's own numbers against placebo's 6–20% Keynan 2010. Score it with a numeric rating scale twice daily and a fixed provoking activity, because a fortnight of memory is not data.
3. The prediction that cuts against the product: no measurable increase in blood flow, and possibly a decrease. The published pharmacology has agmatine inhibiting nitric oxide synthase Reis 2000, and any competition with arginine at cationic amino acid transporters would push the same way. The available home read-out is a tape measure: mid-arm circumference immediately after a fixed set protocol, three sessions on and three sessions off, same time of day. If the pump is real it will show as centimetres. Predict it will not.
4. If you want to test the mood and pain mechanism rather than the marketing, use a fixed instrument and a fixed window. NMDA channel block and imidazoline signaling are slow, daily-dosing mechanisms Halaris 2007; two weeks at a gram or more, with a standard depression or pain inventory scored at day 0 and day 14, is the design the human literature actually supports Keynan 2010.
What will fool you: a pre-workout stack. Agmatine is almost never sold alone — it arrives beside citrulline, beta-alanine and caffeine, all three of which have their own acute effects, one of which genuinely does raise nitric oxide. Attributing the pump to the ingredient with no performance trial behind it is the single commonest error in this category.
What nobody has tested yet
There is no human pharmacokinetic study of oral agmatine sulfate. No time to peak, no peak concentration, no half-life, no measure of how much survives intestinal diamine oxidase. Everything on every label — the dose, the timing, the twice-daily schedule — is invented in the absence of that study. A single-dose pharmacokinetic study in twelve people would cost less than one marketing photoshoot and would be the most useful paper published on this compound in twenty years.
Nobody has tested the nitric oxide claim in either direction. The contradiction at the top of this page — a nitric oxide synthase inhibitor Reis 2000 sold as a nitric oxide booster — is resolvable in an afternoon: flow-mediated dilation of the brachial artery, or plasma nitrite and nitrate, before and after an acute 1 g dose. No published study has done it, and the result would either rescue or retire the entire performance market for this ingredient.
No controlled trial has ever measured a performance outcome. Not strength, not power, not muscle thickness, not repetitions to failure. The one randomized human trial is a pain trial Keynan 2010. For an ingredient sold almost exclusively into sport, that absence is the headline finding rather than a footnote.
And long-term safety rests on one person. The five-year high-dose safety record is a case report of a single individual Gilad 2014. A case series of a hundred long-term users with a comprehensive metabolic panel, a complete blood count and blood pressure would move this from anecdote to evidence, and nobody has assembled one.
Agmatine — its own safety story, not its category's
Blood pressure is this compound's real interaction and it follows from a named receptor. Imidazoline I1 agonism is the mechanism shared with moxonidine and rilmenidine Reis 2000Halaris 2007, so the effect is additive with every antihypertensive class and particularly with alpha-2 agonists such as clonidine. Stacked on a beta-blocker or a diuretic in an older reader, symptomatic hypotension on standing is the predictable consequence. Measure in the first fortnight rather than waiting to feel it.
The NMDA and monoamine overlap is the interaction the card raises and nobody has quantified. Agmatine blocks the NMDA channel and acts at alpha-2 adrenergic sites Reis 2000, which are the same systems targeted by ketamine, by memantine and by several antidepressant classes. Adding it to an SSRI, an SNRI, a monoamine oxidase inhibitor or an NMDA-active drug is a combination with a mechanistic rationale for interaction and no human data at all. That is not a reason to panic; it is a reason not to start it in the same month as a psychiatric medication change, when neither you nor your prescriber could attribute what happens next.
Dose-dependent gut effects, and the reason is the dose itself. Diarrhea and nausea are the common complaints and they cluster at the gram-plus doses the pain trial used Keynan 2010. Agmatine is catabolized to putrescine, a polyamine with its own osmotic and mucosal effects, which is a plausible mechanistic contributor and has not been studied.
The honest boundary on long-term use. The five-year record is one patient Gilad 2014; the controlled trial ran fourteen days Keynan 2010. An ingredient taken daily and indefinitely by healthy people is supported by two weeks of controlled human safety data. Pregnancy and breastfeeding are unstudied, and so is use in anyone under eighteen.
Sources read for this page
- Reis DJ, Regunathan S. Is agmatine a novel neurotransmitter in brain?. Trends in Pharmacological Sciences 2000 · PMID 10785653
- Halaris A, Plietz J. Agmatine: metabolic pathway and spectrum of activity in brain.. CNS Drugs 2007 · PMID 17927294
- Keynan O, et al. Safety and Efficacy of Dietary Agmatine Sulfate in Lumbar Disc-associated Radiculopathy. An Open-label, Dose-escalating Study Followed by a Randomized, Double-blind, Placebo-controlled Trial. Pain Medicine 2010 · PMID 20447305
- Rosenberg ML, et al. Evidence for Dietary Agmatine Sulfate Effectiveness in Neuropathies Associated with Painful Small Fiber Neuropathy. A Pilot Open-Label Consecutive Case Series Study. Nutrients 2020 · PMID 32102167
- Gilad GM, Gilad VH. Long-term (5 years), high daily dosage of dietary agmatine--evidence of safety: a case report. Journal of Medicinal Food 2014 · PMID 25247837
How you would know if it worked
There is no blood test for this one. That is not a criticism — it is a fact about the effect, and it changes how you should judge it.
- What to watch: The pump during the session, if that is what you bought it for — and be honest that a pump is a sensation rather than an outcome, so score it as one: rate fullness 0 to 10 on the same exercises at the same point in the session. If you took it for mood or for pain, those are separate scores kept separately, and the human data behind both is thin.
- How long before it means anything: Five or six sessions, alternating with and without at 500 to 1,000 mg pre-workout. The effect is acute, nothing accumulates, and there is no reason to run it for months before deciding.
- What will fool you: The rest of the pre-workout. Agmatine is nearly always stacked with citrulline or arginine, which produce the same sensation through the same pathway — and the pump is the most suggestible thing in a gym, moving with carbohydrate intake, water, rep range and how warm you are. A pump is also not hypertrophy. The two get equated constantly, and one of them is gone within the hour.
Run it one variable at a time. Starting three things in one week means a result you cannot attribute, which is the same as no result.
Agmatine — safety & side effects
- GI upset and diarrhea are common at higher doses.
- Lowers blood pressure; additive with antihypertensives.
- Long-term safety has not been characterized — the trials run weeks to months, not years. That is a real limit on what anyone can tell you about daily use for a decade. The human data are thin relative to how it is marketed. Some interaction with antidepressants is theoretically plausible given its activity at NMDA and imidazoline receptors.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this against it with a pharmacist or doctor — pharmacists are underused and free.
- When to take it, and what to take it with
- Which form actually absorbs
- Who it's worth it for
- Best-in-class brand pick
- Coach Cam's stacks and notes
- Fasted or with food, and when in the day
- Morning or night, and why that window
- Around training, or deliberately away from it
- What it must not share a window with
Everything above is free and stays free. Skool is where it becomes a plan — Agmatine in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Agmatine
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| Complete Blood Count (CBC) with Differential | Hemoglobin sets your ceiling for endurance work |
| Ferritin | Low iron limits performance long before anemia shows |
| Total Testosterone | Drops under genuine overreaching |
| Comprehensive Metabolic Panel (CMP) | Kidney and electrolytes under heavy training load |
The Athletic Performance & Recovery panel covers these in one order — 12 markers, $207.90 with the discount applied.
Check results you already have → · All 103 markers A–Z
Agmatine — frequently asked questions
What is Agmatine?
An arginine metabolite used pre-workout for nitric-oxide pumps and as a neuromodulator for mood and pain support.
What is the suggested dose of Agmatine?
500–1,000 mg pre-workout. This is a general reference for education only — statements have not been evaluated by the FDA and this is not medical advice.
Where can I find Agmatine dosing and the full breakdown?
The suggested dose and the full evidence — clinical, correlative and theoretical — are on this page. What's inside Skool is when to take it, which form actually absorbs, the brand worth buying and Coach Cam's stacks.
Where can I buy Agmatine?
Coach Cam sources Agmatine from vetted, top-rated brands on iHerb — use the buy link on this page.
What Agmatine is used for
Agmatine appears under 1 goal in the goal router.
Related Performance supplements
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.